|
Fusion gene ID: 32442 |
FusionGeneSummary for RXRA_WDR5 |
Fusion gene summary |
Fusion gene information | Fusion gene name: RXRA_WDR5 | Fusion gene ID: 32442 | Hgene | Tgene | Gene symbol | RXRA | WDR5 | Gene ID | 6256 | 11091 |
Gene name | retinoid X receptor alpha | WD repeat domain 5 | |
Synonyms | NR2B1 | BIG-3|CFAP89|SWD3 | |
Cytomap | 9q34.2 | 9q34.2 | |
Type of gene | protein-coding | protein-coding | |
Description | retinoic acid receptor RXR-alphanuclear receptor subfamily 2 group B member 1retinoid X nuclear receptor alpha | WD repeat-containing protein 5BMP2-induced 3-kb gene proteinSWD3, Set1c WD40 repeat protein, homologcilia and flagella associated protein 89 | |
Modification date | 20180522 | 20180523 | |
UniProtAcc | P19793 | P61964 | |
Ensembl transtripts involved in fusion gene | ENST00000481739, ENST00000356384, ENST00000540193, | ENST00000358625, ENST00000425041, | |
Fusion gene scores | * DoF score | 7 X 4 X 4=112 | 2 X 2 X 1=4 |
# samples | 8 | 2 | |
** MAII score | log2(8/112*10)=-0.485426827170242 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(2/4*10)=2.32192809488736 | |
Context | PubMed: RXRA [Title/Abstract] AND WDR5 [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | RXRA | GO:0000122 | negative regulation of transcription by RNA polymerase II | 17426122 |
Hgene | RXRA | GO:0019048 | modulation by virus of host morphology or physiology | 11915042 |
Hgene | RXRA | GO:0035357 | peroxisome proliferator activated receptor signaling pathway | 10195690 |
Hgene | RXRA | GO:0045944 | positive regulation of transcription by RNA polymerase II | 12037571|20219900 |
Hgene | RXRA | GO:0051289 | protein homotetramerization | 7831303 |
Tgene | WDR5 | GO:0043966 | histone H3 acetylation | 18838386 |
Tgene | WDR5 | GO:0043981 | histone H4-K5 acetylation | 20018852 |
Tgene | WDR5 | GO:0043982 | histone H4-K8 acetylation | 20018852 |
Tgene | WDR5 | GO:0043984 | histone H4-K16 acetylation | 20018852 |
Tgene | WDR5 | GO:0051568 | histone H3-K4 methylation | 17355966|19556245 |
Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
TCGA | RV | LIHC | TCGA-2Y-A9GZ-01A | RXRA | chr9 | 137218505 | + | WDR5 | chr9 | 137017105 | + |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
Frame-shift | ENST00000481739 | ENST00000358625 | RXRA | chr9 | 137218505 | + | WDR5 | chr9 | 137017105 | + |
Frame-shift | ENST00000481739 | ENST00000425041 | RXRA | chr9 | 137218505 | + | WDR5 | chr9 | 137017105 | + |
intron-3CDS | ENST00000356384 | ENST00000358625 | RXRA | chr9 | 137218505 | + | WDR5 | chr9 | 137017105 | + |
intron-3CDS | ENST00000356384 | ENST00000425041 | RXRA | chr9 | 137218505 | + | WDR5 | chr9 | 137017105 | + |
intron-3CDS | ENST00000540193 | ENST00000358625 | RXRA | chr9 | 137218505 | + | WDR5 | chr9 | 137017105 | + |
intron-3CDS | ENST00000540193 | ENST00000425041 | RXRA | chr9 | 137218505 | + | WDR5 | chr9 | 137017105 | + |
Top |
FusionProtFeatures for RXRA_WDR5 |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
RXRA | WDR5 |
Receptor for retinoic acid. Retinoic acid receptors bindas heterodimers to their target response elements in response totheir ligands, all-trans or 9-cis retinoic acid, and regulate geneexpression in various biological processes. The RAR/RXRheterodimers bind to the retinoic acid response elements (RARE)composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The highaffinity ligand for RXRs is 9-cis retinoic acid. RXRA serves as acommon heterodimeric partner for a number of nuclear receptors. Inthe absence of ligand, the RXR-RAR heterodimers associate with amultiprotein complex containing transcription corepressors thatinduce histone acetylation, chromatin condensation andtranscriptional suppression. On ligand binding, the corepressorsdissociate from the receptors and associate with the coactivatorsleading to transcriptional activation. The RXRA/PPARA heterodimeris required for PPARA transcriptional activity on fatty acidoxidation genes such as ACOX1 and the P450 system genes.{ECO:0000269|PubMed:10195690, ECO:0000269|PubMed:11162439,ECO:0000269|PubMed:11915042, ECO:0000269|PubMed:20215566}. | Contributes to histone modification. May position the N-terminus of histone H3 for efficient trimethylation at 'Lys-4'. Aspart of the MLL1/MLL complex it is involved in methylation anddimethylation at 'Lys-4' of histone H3. H3 'Lys-4' methylationrepresents a specific tag for epigenetic transcriptionalactivation. As part of the NSL complex it may be involved inacetylation of nucleosomal histone H4 on several lysine residues.May regulate osteoblasts differentiation.{ECO:0000269|PubMed:16600877, ECO:0000269|PubMed:16829960,ECO:0000269|PubMed:19103755, ECO:0000269|PubMed:19556245,ECO:0000269|PubMed:20018852}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for RXRA_WDR5 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
* Fusion transcript sequences (only coding sequence (CDS) region). |
* Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for RXRA_WDR5 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
RXRA | BRD8, NRBF2, CTNNB1, NCOA6, GADD45G, GADD45A, DNTTIP2, RNF8, NR4A1, HDAC3, HDAC4, TDG, THRB, PML, UBQLN4, TMPRSS3, RARA, POU2F1, NCOA3, MYOD1, NRIP1, NR0B2, EDF1, CTSL, TADA3, BCL3, NR1H2, NR1H4, NFKBIB, RELA, NFKB1, TBP, POU2F2, NR2F6, PPARA, NR1H3, TRIM24, PPARGC1A, SP1, PPARG, ITGB3BP, NPAS2, CLOCK, ARNTL, THRA, NR1I3, NCOA2, NR2E3, VDR, MED24, FUS, SNW1, NCOA1, IGFBP3, NCOR2, TAF1B, MED1, POLR2A, SMARCA4, RARB, GRIP1, NCOR1, SRC, CTCF, MAPK3, MAPK1, RARG, PPARD, NR1I2, KIF1A, NR4A2, MED25, GSK3B, CSNK2B, CASP2, TK1, PLK1, RPS6KA6, SMN1, PSMC5, ROBO4, TRIM32, EP300, BHLHE40, BHLHE41, ARID5A, RAD54L2, JAZF1, SMAD2, PRKD2, CHD9, STAT1, GK, NR3C2, ACVR1B, NCOA4, ALOX15B, NSD1, CNOT1, UBE2I, RXRA, TRIP4, SMARCD3, SRF, ZBTB16, KLF5, DNMT3L, TRAF2, PIK3R1, RXRG, TRIM25, SMARCB1 | WDR5 | MBIP, PASK, KMT2A, ASH2L, HCFC1, HCFC2, MEN1, RBBP5, CXXC1, SETD1A, KDM6A, CHD8, SETD1B, PHF8, MYB, IKBKG, ZNF335, KANSL1, NCOA6, CUL4A, CUL4B, DTL, GRWD1, RFWD2, SNRNP40, WDR26, WDR5B, PAFAH1B1, NLE1, WDR12, CIAO1, WDR53, WDR59, WDR61, HIST1H3A, MLLT1, TP53, KAT8, KMT2D, HIST1H1C, PAX7, PAXIP1, USF1, PAGR1, POU5F1, KDM1B, KAT6A, WDR82, TADA2A, TERF2, PSMC5, CREBBP, CARM1, MAX, PYGO2, UBC, HIST3H3, HDAC5, ESR1, PSMA3, MAVS, TRAF3, TRAF6, MOXD1, MYBBP1A, CSRP2BP, PIK3CA, PITX2, KDM4B, HDGF, DPY30, KMT2B, HDAC3, TWIST1, KMT2C, SRY, PCGF6, RNF2, RYBP, YAF2, RING1, TERF2IP, CUL3, CUL1, COPS5, CAND1, PRNP, ATN1, YEATS2, DR1, KAT2B, KAT2A, TADA3, CCDC101, APP, USP1, ATP6V1B2, UNC45A, TTK, CSE1L, VPS35, PPP1CB, BARD1, KDM6B, HDAC1, SRPK2, CSNK2A2, CSNK1E, SENP3, NFE4, PRMT5, ING2, HSF2, ZXDC, SSX2IP, RUSC1-AS1, PKN1, EP300, HIST1H1A, HIST4H4, BMI1, ARNTL, BHLHE41, E2F6, BOD1, ZZZ3, PDPK1, MGA, L3MBTL2, BOD1L1, PPP1R3F, FAM199X, RERE, SESN2, KANSL2, AUTS2, NTRK1, HARS, EIF2D, HELLS, KIF2C, SAC3D1, SERBP1, XPO1, PML, KIF23, RACGAP1, CEP55, CHMP1B, ECT2, PDCD6IP, TSG101, PRC1, SNW1, CHD7, MYCN, WWP2, HDAC2, PTPN21, AGMAT, CYLD, INO80B, SLC7A6OS, FOXA1, MYC, BRCA1 |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for RXRA_WDR5 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Hgene | RXRA | P19793 | DB00210 | Adapalene | Retinoic acid receptor RXR-alpha | small molecule | approved |
Hgene | RXRA | P19793 | DB00459 | Acitretin | Retinoic acid receptor RXR-alpha | small molecule | approved |
Hgene | RXRA | P19793 | DB00307 | Bexarotene | Retinoic acid receptor RXR-alpha | small molecule | approved|investigational |
Hgene | RXRA | P19793 | DB00412 | Rosiglitazone | Retinoic acid receptor RXR-alpha | small molecule | approved|investigational |
Hgene | RXRA | P19793 | DB00523 | Alitretinoin | Retinoic acid receptor RXR-alpha | small molecule | approved|investigational |
Hgene | RXRA | P19793 | DB01393 | Bezafibrate | Retinoic acid receptor RXR-alpha | small molecule | approved|investigational |
Hgene | RXRA | P19793 | DB00755 | Tretinoin | Retinoic acid receptor RXR-alpha | small molecule | approved|investigational|nutraceutical |
Hgene | RXRA | P19793 | DB00749 | Etodolac | Retinoic acid receptor RXR-alpha | small molecule | approved|investigational|vet_approved |
Hgene | RXRA | P19793 | DB01436 | Alfacalcidol | Retinoic acid receptor RXR-alpha | small molecule | approved|nutraceutical |
Top |
RelatedDiseases for RXRA_WDR5 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | RXRA | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
Hgene | RXRA | C0040136 | Thyroid Neoplasm | 1 | CTD_human |
Hgene | RXRA | C0149940 | Sciatic Neuropathy | 1 | CTD_human |
Hgene | RXRA | C0345967 | Malignant mesothelioma | 1 | CTD_human |
Hgene | RXRA | C1862939 | AMYOTROPHIC LATERAL SCLEROSIS 1 | 1 | CTD_human |